Collections

Filters ​

  • Focus |

    The present system for commercializing biomedical research remains woefully inefficient and underpowered. This issue of Nature Biotechnologycollects several articles that describe alternatives to current pathways for clinical translation of academic discovery.

  • Focus |

    Increased understanding of the molecular defects associated with malignancies is opening up new opportunities in diagnosis and therapy. This focus issue of Nature Biotechnology highlights a selection of new technologies that promise to facilitate the development of more effective cancer treatments.

  • Focus |

    Sixteen years after the commercialization of crops produced by traditional transgenic technology, a raft of new approaches are opening new opportunities in plant biotechnology. This focus issue of Nature Biotechnologyhighlights these technologies and their impact on plant breeding and their impact on regulatory oversight.

  • Focus |

    Nature Biotechnology is 15! We have brought together a collection of commentaries, features and profiles from thought-leaders in the sector that touch upon the issues that are likely to be important in the coming years.

  • Focus |

    Recent years have seen an explosive increase in our knowledge of such epigenetic mechanisms as chromatin remodeling and DNA methylation in development and disease. This focus issue discusses the current state of the field and how current insights can be translated into practical applications.

  • Focus |

    Articles from Nature Biotechnology and The Pharmacogenomics Journal that explore best practices for developing and validating predictive models based on data from gene expression and genotyping microarrays. These report the second phase of a collaboration between industry, academic and government researchers as part of the MicroArray Quality Control (MAQC) consortium.

  • Focus |

    The first formal results of the Predictive Testing Safety Consortium, a community-wide effort involving over 190 scientists from industry, non-profit institutions and regulators that set out to qualify nephrotoxicity biomarkers in the preclinical and clinical settings.

  • Focus |

    The latest iteration of genetic engineering offers the prospect of the design and construction of new life forms from biological parts, devices and systems. Although still in its infancy, this focus discusses some of the progress in synthetic biology toward practical applications.

  • Focus |

    A series of articles that focuses on the massively parallel sequencing technology that are making progress in the quest for a $1000 human genome sequence.

  • Focus |

    This issue provides several articles focusing on antiviral therapy. Additional material, brought together in a joint focus with Nature Reviews Drug Discoverysupported by our principal sponsor Pfizer and our supporting sponsor Gilead.

  • Focus |

    A collection of articles from Nature Biotechnology, brought together in a joint focus with Nature Reviews Drug Discovery, on the science and business of antibacterial discovery and development.

  • Focus |

    The first formal results of a consortium of over 150 regulatory, industrial and academic scientists that set out to conduct a cross-platform analysis of DNA microarray expression data obtained from two, commercially available RNA samples.